David Einhorn
Greenlight Capital
David Einhorn NeuBase Therapeutics Inc stake
total: 357
Greenlight Capital NBSE trades
- Total transactions:
- 6
- New positions:
- 1
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 1
- Held since:
- 2019 Q3
- Held for:
- 19 quarters
- Latest activity:
- 2024 Q2
According to 2026 Q2 report, David Einhorn doesn't hold any NeuBase Therapeutics Inc (NBSE) shares. To date, the estimated cost basis is nearly $111.27 for "buy" trades and estimated average "sell" price is $0.45. Greenlight Capital first purchased NBSE in 2019 Q3, initially acquiring 76,923 shares. Since the initial investment in NeuBase Therapeutics Inc (NBSE), Greenlight Capital has made 5 more transactions.
When did David Einhorn sell NeuBase Therapeutics Inc (NBSE)?
David Einhorn sold off the entire NeuBase Therapeutics Inc (NBSE) position in 2024 Q2.
When did David Einhorn buy NeuBase Therapeutics Inc (NBSE)?
David Einhorn first invested in NeuBase Therapeutics Inc (NBSE) in 2019 Q3 at the reported quarter-end price of $99.80 per share.
What's the cost basis of Greenlight Capital's NBSE stake?
The estimated cost basis for NeuBase Therapeutics Inc (NBSE) stake is around $111.27 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $111.27
- Weighted AVG sell price:
- $0.45
David Einhorn's historical trades in NeuBase Therapeutics Inc
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q2
|
0.00%
|
0
|
$0.45
|
|
-100% (-136,350)
|
-0%
|
|
2023 Q2
|
0.01%
|
136,350
|
$1.87
|
$254,975
|
-0.00% (-1.35)
|
0%
|
|
2021 Q2
|
0.82%
|
136,351.35
|
$95.80
|
$13,062,000
|
+34.53% (+35,000)
|
+0.21%
|
|
2020 Q3
|
1.27%
|
$151.81
|
+6.50% (+6,190)
|
|||
|
2020 Q2
|
1.83%
|
$175.61
|
+23.71% (+18,238.25)
|
|||
|
2019 Q3
|
0.55%
|
$99.80
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.